Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Ondine Biomedical, Inc. ( (GB:OBI) ) is now available.
Ondine Biomedical Inc. announced a proposed fundraising of approximately £11 million to support its strategic initiatives, including a Phase 3 clinical trial and commercial growth efforts. The fundraising will involve a placing and subscription of new common shares, with company directors participating in the subscription. The funds are expected to extend the company’s cash runway through the first half of 2026. In the first half of 2025, Ondine focused on clinical programs and commercial expansion, achieving a 41% increase in facility adoption of its Steriwave product and an 18% revenue growth, setting a strong foundation for future growth.
The most recent analyst rating on (GB:OBI) stock is a Buy with a £55.00 price target. To see the full list of analyst forecasts on Ondine Biomedical, Inc. stock, see the GB:OBI Stock Forecast page.
More about Ondine Biomedical, Inc.
Ondine Biomedical Inc. is a Canadian life sciences company specializing in light-activated antimicrobial therapies, known as photodisinfection. The company has a range of investigational products based on its proprietary technology, aimed at innovating in the field of antimicrobial treatments.
Average Trading Volume: 263,682
Technical Sentiment Signal: Buy
Current Market Cap: £73.3M
Learn more about OBI stock on TipRanks’ Stock Analysis page.